Pharmaceutical compositions containing lipase inhibitors
AssigneeHoffmann-La Roche Inc.
InventorsPasschier Christiaan de Smidt, Paul Hadvary, Hans Lengsfeld, Thomas Rades, Hans Steffen, Joseph Tardio
Life of this patent
Estimating the term…
Abstract
A pharmaceutical composition comprises at least one inhibitor of lipases, preferably an inhibitor of gastrointestinal and pancreatic lipases, such as orlistat, at least one surfactant, and at least one dispersant.
Claims23
A pharmaceutical dosage form comprising (i) orlistat (ii) at least one non-ionic or zwitterionic surfactant selected from the group consisting of vitamin E polyethylene glycol 1000 succinate, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene stearates, polyoxyethylene alkyl ethers, polyoxyethylene castor oils, polyglycolyzed glycerides, transesterified and (poly)ethoxylated oils, sorbitan fatty acid esters, poloxamers, lecithins, sugar esters, and mixtures thereof, and (iii) at least one dispersant.
A method for improving the efficacy of orlistat in a mammal in need thereof comprising administering to said mammal a pharmaceutical dosage form comprising (i) orlistat present in an amount of 60 mg or less (ii) at least one non-ionic or zwitterionic surfactant selected from the group consisting of vitamin E polyethylene glycol 1000 succinate, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene stearates, polyoxyethylene alkyl ethers, polyoxyethylene castor oils, polyglycolyzed glycerides, transesterified and (poly)ethoxylated oils, sorbitan fatty acid esters, poloxamers, lecithins, sugar esters, and mixtures thereof, and (iii) at least one dispersant.
Dependencies are inferred from the claim text.